|
1
|
Torre LA, Siegel RL and Jemal A: Lung
cancer statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pao W and Girard N: New driver mutations
in non-small-cell lung cancer. Lancet Oncol. 12:175–180. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Govindan R, Ding L, Griffith M,
Subramanian J, Dees ND, Kanchi KL, Maher CA, Fulton R, Fulton L,
Wallis J, et al: Genomic landscape of non-small cell lung cancer in
smokers and never-smokers. Cell. 150:1121–1134. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Imielinski M, Berger AH, Hammerman PS,
Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M,
Sivachenko A, et al: Mapping the hallmarks of lung adenocarcinoma
with massively parallel sequencing. Cell. 150:1107–1120. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Devarakonda S, Morgensztern D and Govindan
R: Genomic alterations in lung adenocarcinoma. Lancet Oncol.
16:e342–e351. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chapman AM, Sun KY, Ruestow P, Cowan DM
and Madl AK: Lung cancer mutation profile of EGFR, ALK, and KRAS:
Meta-analysis and comparison of never and ever smokers. Lung
Cancer. 102:122–134. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gibelin C and Couraud S: Somatic
alterations in lung cancer: Do environmental factors matter? Lung
Cancer. 100:45–52. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hirsch FR, Scagliotti GV, Mulshine JL,
Kwon R, Curran WJ Jr, Wu YL and Paz-Ares L: Lung cancer: Current
therapies and new targeted treatments. Lancet. 389:299–311. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Okabe T, Okamoto I, Tamura K, Terashima M,
Yoshida T, Satoh T, Takada M, Fukuoka M and Nakagawa K:
Differential constitutive activation of the epidermal growth factor
receptor in non-small cell lung cancer cells bearing EGFR gene
mutation and amplification. Cancer Res. 67:2046–2053. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ono M and Kuwano M: Molecular mechanisms
of epidermal growth factor receptor (EGFR) activation and response
to gefitinib and other EGFR-targeting drugs. Clin Cancer Res.
12:7242–7251. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Taron M, Ichinose Y, Rosell R, Mok T,
Massuti B, Zamora L, Mate JL, Manegold C, Ono M, Queralt C, et al:
Activating mutations in the tyrosine kinase domain of the epidermal
growth factor receptor are associated with improved survival in
gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer
Res. 11:5878–5885. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee JK, Hahn S, Kim DW, Suh KJ, Keam B,
Kim TM, Lee SH and Heo DS: Epidermal growth factor receptor
tyrosine kinase inhibitors vs conventional chemotherapy in
non-small cell lung cancer harboring wild-type epidermal growth
factor receptor: A meta-analysis. JAMA. 311:1430–1437. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nan X, Xie C, Yu X and Liu J: EGFR TKI as
first-line treatment for patients with advanced EGFR
mutation-positive non-small-cell lung cancer. Oncotarget.
8:75712–75726. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fogli S, Polini B, Del Re M, Petrini I,
Passaro A, Crucitta S, Rofi E and Danesi R: EGFR-TKIs in
non-small-cell lung cancer: Focus on clinical pharmacology and
mechanisms of resistance. Pharmacogenomics. 19:727–740. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhou Y, Li S, Hu YP, Wang J, Hauser J,
Conway AN, Vinci MA, Humphrey L, Zborowska E, Willson JK, et al:
Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2
tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma
GEO cells to apoptosis. Cancer Res. 66:404–411. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu L, Cao Y, Chen C, Zhang X, McNabola A,
Wilkie D, Wilhelm S, Lynch M and Carter C: Sorafenib blocks the
RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor
cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer
Res. 66:11851–11858. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chiba K, Kataoka H, Seki N, Shimano K,
Koyama M, Fukunari A, Sugahara K and Sugita T: Fingolimod (FTY720),
sphingosine 1-phosphate receptor modulator, shows superior efficacy
as compared with interferon-beta in mouse experimental autoimmune
encephalomyelitis. Int Immunopharmacol. 11:366–372. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sonoda Y, Yamamoto D, Sakurai S, Hasegawa
M, Aizu-Yokota E, Momoi T and Kasahara T: FTY720, a novel
immunosuppressive agent, induces apoptosis in human glioma cells.
Biochem Biophys Res Commun. 281:282–288. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Azuma H, Takahara S, Ichimaru N, Wang JD,
Itoh Y, Otsuki Y, Morimoto J, Fukui R, Hoshiga M and Ishihara T:
Marked prevention of tumor growth and metastasis by a novel
immunosuppressive agent, FTY720, in mouse breast cancer models.
Cancer Res. 62:1410–1419. 2002.PubMed/NCBI
|
|
22
|
Lee TK, Man K, Ho JW, Sun CK, Ng KT, Wang
XH, Wong YC, Ng IO, Xu R and Fan ST: FTY720 induces apoptosis of
human hepatoma cell lines through PI3-K-mediated Akt
dephosphorylation. Carcinogenesis. 25:2397–2405. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schmid G, Guba M, Papyan A, Ischenko I,
Brückel M, Bruns CJ, Jauch KW and Graeb C: FTY720 inhibits tumor
growth and angiogenesis. Transplant Proc. 37:110–111. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang L, Wang HD, Ji XJ, Cong ZX, Zhu JH
and Zhou Y: FTY720 for cancer therapy (Review). Oncol Rep.
30:2571–2578. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
White C, Alshaker H, Cooper C, Winkler M
and Pchejetski D: The emerging role of FTY720 (Fingolimod) in
cancer treatment. Oncotarget. 7:23106–23127. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang N, Qi Y, Wadham C, Wang L, Warren A,
Di W and Xia P: FTY720 induces necrotic cell death and autophagy in
ovarian cancer cells: A protective role of autophagy. Autophagy.
6:1157–1167. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liao A, Hu R, Zhao Q, Li J, Li Y, Yao K,
Zhang R, Wang H, Yang W and Liu Z: Autophagy induced by FTY720
promotes apoptosis in U266 cells. Eur J Pharm Sci. 45:600–605.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang L, Wang H, Ding K and Xu J: FTY720
induces autophagy-related apoptosis and necroptosis in human
glioblastoma cells. Toxicol Lett. 236:43–59. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li J, Wang SW, Zhang DS, Sun Y, Zhu CY,
Fei Q, Hu J, Zhang C and Sun YM: FTY720-induced enhancement of
autophagy protects cells from FTY720 cytotoxicity in colorectal
cancer. Oncol Rep. 35:2833–2842. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Alinari L, Mahoney E, Patton J, Zhang X,
Huynh L, Earl CT, Mani R, Mao Y, Yu B, Quinion C, et al: FTY720
increases CD74 expression and sensitizes mantle cell lymphoma cells
to milatuzumab-mediated cell death. Blood. 118:6893–6903. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ahmed D, de Verdier PJ, Ryk C, Lunqe O,
Stal P and Flygare J: FTY720 (Fingolimod) sensitizes hepatocellular
carcinoma cells to sorafenib-mediated cytotoxicity. Pharmacol Res
Perspect. 3:e001712015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tay KH, Liu X, Chi M, Jin L, Jiang CC, Guo
ST, Verrills NM, Tseng HY and Zhang XD: Involvement of vacuolar
H(+)-ATPase in killing of human melanoma cells by the sphingosine
kinase analogue FTY720. Pigment Cell Melanoma Res. 28:171–183.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li X, Wang MH, Qin C, Fan WH, Tian DS and
Liu JL: Fingolimod suppresses neuronal autophagy through the
mTOR/p70S6K pathway and alleviates ischemic brain damage in mice.
PLoS One. 12:e01887482017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Levy JMM, Towers CG and Thorburn A:
Targeting autophagy in cancer. Nat Rev Cancer. 17:528–542. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ashburn TT and Thor KB: Drug
repositioning: Identifying and developing new uses for existing
drugs. Nat Rev Drug Discov. 3:673–683. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jahchan NS, Dudley JT, Mazur PK, Flores N,
Yang D, Palmerton A, Zmoos AF, Vaka D, Tran KQ, Zhou M, et al: A
drug repositioning approach identifies tricyclic antidepressants as
inhibitors of small cell lung cancer and other neuroendocrine
tumors. Cancer Discov. 3:1364–1377. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pushpakom S, Iorio F, Eyers PA, Escott KJ,
Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C, et
al: Drug repurposing: Progress challenges and recommendations. Nat
Rev Drug Discov. 2018.PubMed/NCBI
|
|
38
|
Sugita S, Ito K, Yamashiro Y, Moriya S,
Che XF, Yokoyama T, Hiramoto M and Miyazawa K: EGFR-independent
autophagy induction with gefitinib and enhancement of its cytotoxic
effect by targeting autophagy with clarithromycin in non-small cell
lung cancer cells. Biochem Biophys Res Commun. 461:28–34. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang M and Kaufman RJ: The impact of the
endoplasmic reticulum protein-folding environment on cancer
development. Nat Rev Cancer. 14:581–597. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
McConkey DJ: The integrated stress
response and proteotoxicity in cancer therapy. Biochem Biophys Res
Commun. 482:450–453. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang M, Law ME, Castellano RK and Law BK:
The unfolded protein response as a target for anticancer
therapeutics. Crit Rev Oncol Hematol. 127:66–79. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kawaguchi T, Miyazawa K, Moriya S, Ohtomo
T, Che XF, Naito M, Itoh M and Tomoda A: Combined treatment with
bortezomib plus bafilomycin A1 enhances the cytocidal effect and
induces endoplasmic reticulum stress in U266 myeloma cells:
Crosstalk among proteasome, autophagy-lysosome and ER stress. Int J
Oncol. 38:643–654. 2011.PubMed/NCBI
|
|
43
|
Moriya S, Che XF, Komatsu S, Abe A,
Kawaguchi T, Gotoh A, Inazu M, Tomoda A and Miyazawa K: Macrolide
antibiotics block autophagy flux and sensitize to bortezomib via
endoplasmic reticulum stress-mediated CHOP induction in myeloma
cells. Int J Oncol. 42:1541–1550. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kaizuka T, Morishita H, Hama Y, Tsukamoto
S, Matsui T, Toyota Y, Kodama A, Ishihara T, Mizushima T and
Mizushima N: An autophagic flux probe that releases an internal
control. Mol Cell. 64:835–849. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
O'Prey J, Sakamaki J, Baudot AD, New M,
Van Acker T, Tooze SA, Long JS and Ryan KM: Application of
CRISPR/Cas9 to autophagy research. Methods Enzymol. 588:79–108.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Krypuy M, Newnham GM, Thomas DM, Conron M
and Dobrovic A: High resolution melting analysis for the rapid and
sensitive detection of mutations in clinical samples: KRAS codon 12
and 13 mutations in non-small cell lung cancer. BMC Cancer.
6:2952006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wilhelm SM, Carter C, Tang L, Wilkie D,
McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al:
BAY 43–9006 exhibits broad spectrum oral antitumor activity and
targets the RAF/MEK/ERK pathway and receptor tyrosine kinases
involved in tumor progression and angiogenesis. Cancer Res.
64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chou TC: Theoretical basis, experimental
design, and computerized simulation of synergism and antagonism in
drug combination studies. Pharmacol Rev. 58:621–681. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Mukai S, Moriya S, Hiramoto M, Kazama H,
Kokuba H, Che XF, Yokoyama T, Sakamoto S, Sugawara A, Sunazuka T,
et al: Macrolides sensitize EGFR-TKI-induced non-apoptotic cell
death via blocking autophagy flux in pancreatic cancer cell lines.
Int J Oncol. 48:45–54. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yoshii SR and Mizushima N: Monitoring and
measuring autophagy. Int J Mol Sci. 18:2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Mauvezin C and Neufeld TP: Bafilomycin A1
disrupts autophagic flux by inhibiting both V-ATPase-dependent
acidification and Ca-P60A/SERCA-dependent autophagosome-lysosome
fusion. Autophagy. 11:1437–1438. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Moriya S, Komatsu S, Yamasaki K, Kawai Y,
Kokuba H, Hirota A, Che XF, Inazu M, Gotoh A, Hiramoto M and
Miyazawa K: Targeting the integrated networks of aggresome
formation, proteasome, and autophagy potentiates ER stressmediated
cell death in multiple myeloma cells. Int J Oncol. 46:474–486.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Miyahara K, Kazama H, Kokuba H, Komatsu S,
Hirota A, Takemura J, Hirasawa K, Moriya S, Abe A, Hiramoto M, et
al: Targeting bortezomib-induced aggresome formation using
vinorelbine enhances the cytotoxic effect along with ER stress
loading in breast cancer cell lines. Int J Oncol. 49:1848–1858.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kazama H, Hiramoto M, Miyahara K, Takano N
and Miyazawa K: Designing an effective drug combination for ER
stress loading in cancer therapy using a real-time monitoring
system. Biochem Biophys Res Commun. 501:286–292. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Brewer JW and Diehl JA: PERK mediates
cell-cycle exit during the mammalian unfolded protein response.
Proc Natl Acad Sci USA. 97:12625–12630. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Hamanaka RB, Bennett BS, Cullinan SB and
Diehl JA: PERK and GCN2 contribute to eIF2alpha phosphorylation and
cell cycle arrest after activation of the unfolded protein response
pathway. Mol Biol Cell. 16:5493–5501. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Vincenz L, Jager R, O'Dwyer M and Samali
A: Endoplasmic reticulum stress and the unfolded protein response:
Targeting the Achilles heel of multiple myeloma. Mol Cancer Ther.
12:831–843. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Pluquet O, Pourtier A and Abbadie C: The
unfolded protein response and cellular senescence. A review in the
theme: Cellular mechanisms of endoplasmic reticulum stress
signaling in health and disease. Am J Physiol Cell Physiol.
308:C415–C425. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Nishida Y, Arakawa S, Fujitani K,
Yamaguchi H, Mizuta T, Kanaseki T, Komatsu M, Otsu K, Tsujimoto Y
and Shimizu S: Discovery of Atg5/Atg7-independent alternative
macroautophagy. Nature. 461:654–658. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Yamaguchi H, Arakawa S, Kanaseki T,
Miyatsuka T, Fujitani Y, Watada H, Tsujimoto Y and Shimizu S: Golgi
membrane-associated degradation pathway in yeast and mammals. EMBO
J. 35:1991–2007. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Chen C, Ju R, Shi J, Chen W, Sun F, Zhu L,
Li J, Zhang D, Ye C and Guo L: Carboxyamidotriazole synergizes with
sorafenib to combat non-small cell lung cancer through inhibition
of NANOG and aggravation of apoptosis. J Pharmacol Exp Ther.
362:219–229. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Diaz R, Nguewa PA, Parrondo R,
Perez-Stable C, Manrique I, Redrado M, Catena R, Collantes M,
Peñuelas I, Díaz-González JA and Calvo A: Antitumor and
antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase
inhibitor lapatinib in a lung cancer model. BMC Cancer. 10:1882010.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Saddoughi SA, Gencer S, Peterson YK, Ward
KE, Mukhopadhyay A, Oaks J, Bielawski J, Szulc ZM, Thomas RJ,
Selvam SP, et al: Sphingosine analogue drug FTY720 targets
I2PP2A/SET and mediates lung tumour suppression via activation of
PP2A-RIPK1-dependent necroptosis. EMBO Mol Med. 5:105–121. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Heymach JV, Nilsson M, Blumenschein G,
Papadimitrakopoulou V and Herbst R: Epidermal growth factor
receptor inhibitors in development for the treatment of non-small
cell lung cancer. Clin Cancer Res. 12:4441s–4445s. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
McDermott MS, Browne BC, Conlon NT,
O'Brien NA, Slamon DJ, Henry M, Meleady P, Clynes M, Dowling P,
Crown J and O'Donovan N: PP2A inhibition overcomes acquired
resistance to HER2 targeted therapy. Mol Cancer. 13:1572014.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Janne PA, Engelman JA and Johnson BE:
Epidermal growth factor receptor mutations in non-small-cell lung
cancer: Implications for treatment and tumor biology. J Clin Oncol.
23:3227–3234. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Gainor JF and Shaw AT: Emerging paradigms
in the development of resistance to tyrosine kinase inhibitors in
lung cancer. J Clin Oncol. 31:3987–3996. 2013. View Article : Google Scholar : PubMed/NCBI
|
